

New Management Hires and Attendance at the International ALS/MND Symposium

Highlights:

- PharmAust has strengthened its management team with the appointment of
 - Dr Carol Worth joins as CMC Operations Manager with over 30 years of pharmaceutical industry experience
 - John Clark joins as Clinical Operations Manager with over 20 years of pharmaceutical industry experience in the global management of phase I – IV clinical trials
- Dr Michael Thurn is attending the 34th International Symposium on ALS/MND in Basel, Switzerland, from the 6th to the 8th of December, 2023
- A recent BioPharma Dealmakers article by Nature details 2023 as the biggest year for deals in the Rare CNS Disease space, totalling US\$13.2 billion. doi: <https://doi.org/10.1038/d43747-023-00128-7>

06 December 2023 – Perth, Australia: PharmAust Limited (ASX: PAA) (Company), a clinical-stage biotechnology company, is pleased to announce it has strengthened its management team with the appointment of Dr Carol Worth as CMC Operations Manager and John Clark as Clinical Operations Manager.

Dr Michael Thurn is attending the 34th International Symposium on ALS/MND in Basel, Switzerland, from the 6th to the 8th of December 2023. The International Symposium is the largest annual conference dedicated to ALS and MND research.

PharmAust Chief Executive Officer Dr Michael Thurn commented:

“PharmAust has significantly strengthened its management team with the appointment of Dr Carol Worth and John Clark in preparation for upcoming regulatory and clinical milestones for its development programs. With the recent announcement that all patients had completed the Phase 1 MEND Study of monepantel for motor neurone disease, it was important for PharmAust to carry momentum into the new year to launch a Phase 2 study.

Dr Carol Worth will oversee the GMP manufacture of monepantel and the provision of clinical supplies for our upcoming clinical studies. John Clark will lead global clinical operations as the Company positions itself as a leading developer of neurodegenerative medicines.”

New Management Hires Biographies

Dr Carol Worth brings over 30 years of industry experience and a passion for focusing on quality control and quality assurance. She recently served as Quality Manager at Epichem Pty Ltd as chief Technical Officer at Suda Pharmaceuticals and Solbec Pharmaceuticals. Carol has also led product development programs at Thermalife International Pty Ltd/ Pharmasolv Laboratories Pty Ltd.

John Clark joined PharmAust with over 20 years of pharmaceutical industry experience in phase I – IV clinical trials across numerous therapeutic areas and multiple geographical regions. Most recently, John served as Senior Project Manager at a Global CRO, leading the Clinical Operations team and providing cross-functional oversight on a national CNS trial. Before that, John held various clinical operations leadership roles responsible for implementing clinical programs. John has a proven project management and stakeholder engagement record, with a thorough knowledge of ICH-GCP and regulatory requirements. John earned his B.Sc. in Biomedical Sciences from the University of the West of England.

34th International Symposium on ALS/MND

The International Symposium on ALS/MND is the largest annual conference dedicated to ALS and MND research. This multidisciplinary meeting aims to raise global awareness, share information on managing the condition, support and coordinate international research, create a worldwide identity and improve the quality of care for patients with ALS/MND. Over 1,000 delegates from global pharmaceutical companies, Government Institutions and University research institutes, and not-for-profit ALS/MND Associations worldwide will attend.

PharmAust Chief Executive Officer Dr Michael Thurn commented:

“The international symposium provides an ideal backdrop for PharmAust to engage and update a range of interested parties on the clinical progress of monepantel for the treatment of ALS/MND. The beginning of 2024 is one of the most important periods in the Company's history. There are several exciting opportunities in play at the moment, and this all comes on the back of 2023, the biggest year for deals done in the Rare CNS Disease space. In a recent BioPharma Dealmakers article published by Nature, the number of deals completed in 2023 has already topped 2022. In 2023, at least 47 deals were announced with disclosed values totalling more than \$13 billion¹.”

The Board authorises this announcement.

Enquiries:

Dr Michael Thurn

Chief Executive Officer

investorenquiries@pharmaust.com

P +61 (8) 9202 6814

F +61 (8) 9467 6111

www.pharmaust.com



About Motor Neurone Disease:

According to the International Alliance of ALS/MND Associations, MND affects over 350,000 people globally and kills more than 100,000 people yearly. The disease is invariably fatal, with the average life expectancy of someone with MND being around 27 months. The MND/ALS addressable market is US\$3.6Bn per annum, with the standard of care treatment, Riluzole, only prolonging life on average by 2-3 months.

The disease is progressive, meaning the symptoms get worse over time. MND has no cure and no effective treatment to reverse its progression. Independent studies have shown that one-third of patients die within 12 months after the first diagnosis.

About PharmAust Limited:

PharmAust Limited is listed on the Australian Securities Exchange (code: PAA) and the Frankfurt Stock Exchange (code: ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs, lowering the risks and costs of development.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in Phase 1 clinical studies in humans and Phase 2 clinical studies in dogs. MPL treatment was well-tolerated in humans, demonstrating preliminary evidence of anticancer activity. MPL demonstrated objective anticancer activity in dogs. PAA is uniquely positioned to commercialise MPL for treating human and veterinary cancers and neurodegenerative diseases as it advances a reformulated version of this drug through Phase 1 and 2 clinical studies.

¹ Mark Zipkin, Neurodegeneration and rare diseases drive CNS therapy deals. Biopharma Dealmakers News Feature. 1 December 2023. doi: <https://doi.org/10.1038/d43747-023-00128-7>